Biodexa Pharmaceuticals Plc
BDRX
$7.45
-$0.06-0.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.54M | -2.40M | -1.55M | -1.58M | -2.09M |
| Total Depreciation and Amortization | 93.50K | 88.20K | 74.30K | 75.50K | 85.80K |
| Total Amortization of Deferred Charges | -- | -- | 1.30K | 1.30K | -- |
| Total Other Non-Cash Items | 270.50K | 255.00K | -1.46M | -1.49M | -481.30K |
| Change in Net Operating Assets | -28.70K | -27.10K | -1.83M | -1.86M | -550.00K |
| Cash from Operations | -2.21M | -2.08M | -4.77M | -4.85M | -3.03M |
| Capital Expenditure | -1.30K | -1.30K | -5.80K | -5.90K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -225.10K | -212.20K | 105.70K | 107.40K | -475.60K |
| Cash from Investing | -226.40K | -213.50K | 99.90K | 101.50K | -475.60K |
| Total Debt Issued | -- | -- | 215.50K | 215.50K | -- |
| Total Debt Repaid | -115.50K | -115.50K | -46.50K | -46.50K | -46.50K |
| Issuance of Common Stock | 3.13M | 3.13M | 2.16M | 2.16M | 2.37M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.00K | -5.00K | -376.50K | -376.50K | -- |
| Cash from Financing | 4.01M | 3.78M | 2.51M | 2.55M | 2.93M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.58M | 1.49M | -2.17M | -2.20M | -577.80K |